“Whether the Federal Circuit erred by holding that, whenever the prior art teaches away from a pharmaceutical composition, the written description of a patent claiming that composition can satisfy 35 U.S.C. ยง 112 only if it discloses either experimental data proving efficacy or a detailed theory of why the composition works sufficient to show that it would be effective.”
